Aptamers: A promising chemical antibody for cancer therapy

110Citations
Citations of this article
190Readers
Mendeley users who have this article in their library.

Abstract

Aptamers, also known as chemical antibodies, are single-stranded nucleic acid oligonucleotides which bind to their targets with high specificity and affinity. They are typically selected by repetitive in vitro process termed systematic evolution of ligands by exponential enrichment (SELEX). Owing to their excellent properties compared to conventional antibodies, notably their smaller physical size and lower immunogenicity and toxicity, aptamers have recently emerged as a new class of agents to deliver therapeutic drugs to cancer cells by targeting specific cancer-associated hallmarks. Aptamers can also be structurally modified to make them more flexible in order to conjugate other agents such as nano-materials and therapeutic RNA agents, thus extending their applications for cancer therapy. This review presents the current knowledge on the practical applications of aptamers in the treatment of a variety of cancers.

Cite

CITATION STYLE

APA

Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., & Qiao, L. (2016, March 22). Aptamers: A promising chemical antibody for cancer therapy. Oncotarget. Impact Journals LLC. https://doi.org/10.18632/oncotarget.7178

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free